Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A New Player in Lipid Metabolism Discovered

Published: Monday, August 18, 2014
Last Updated: Monday, August 18, 2014
Bookmark and Share
Specially engineered mice gained no weight, and normal counterparts became obese on the same high-fat, obesity-inducing Western diet.

Specially engineered mice that lacked a particular gene did not gain weight when fed a typical high-fat, obesity-inducing Western diet. Yet, these mice ate the same amount as their normal counterparts that became obese.

The mice were engineered with fat cells that lacked a gene called SEL1L, known to be involved in the clearance of misfolded proteins in the cell’s protein making machinery called the endoplasmic reticulum (ER).

When misfolded proteins are not cleared but accumulate, they destroy the cell and contribute to such diseases as mad cow disease, Type 1 diabetes and cystic fibrosis.

“The million-dollar question is why don’t these mice gain weight? Is this related to its inability to clear misfolded proteins in the ER?” said Ling Qi, associate professor of molecular and biochemical nutrition and senior author of the study published online July 24 in Cell Metabolism. Haibo Sha, a research associate in Qi’s lab, is the paper’s lead author.

Interestingly, the experimental mice developed a host of other problems, including postprandial hypertriglyceridemia, which is characterized by high levels of triglycerides in humans and mice (after a meal) that can lead to heart attacks and strokes if untreated, and fatty livers.

“Although we are yet to find out whether these conditions contribute to the lean phenotype, we found that there was a lipid partitioning defect in the mice lacking SEL1L in fat cells, where fat cells cannot store fat [lipids], and consequently fat goes to the liver. During the investigation of possible underlying mechanisms, we discovered a novel function for SEL1L as a regulator of lipid metabolism,” said Qi.

“We were very excited to find that SEL1L is required for the intracellular trafficking of an enzyme called lipoprotein lipase (LPL), acting as a chaperone,” said Sha. “Using several tissue-specific knockout mouse models, we showed that this is a general phenomenon,” Sha added.

Without LPL, lipids remain in the circulation; fat and muscle cells cannot absorb fat molecules for storage and energy combustion, respectively. Many humans have LPL mutations and develop postprandial hypertriglyceridemia similar to conditions found in fat cell-specific SEL1L-deficient mice, said Qi.

Future work will investigate the role of SEL1L in human patients carrying LPL mutations and determine why fat cell-specific SEL1L-deficient mice remain lean under Western diets, said Sha.

Co-authors include researchers from Cedars-Sinai Medical Center in Los Angeles; Wageningen University in the Netherlands; Georgia State University; University of California, Los Angeles; and the Medical College of Soochow University in China.

The study was funded by the U.S. National Institutes of Health, the Netherlands Organization for Health Research and Development National Institutes of Health, the Cedars-Sinai Medical Center, Chinese National Science Foundation, the American Diabetes Association, Cornell’s Center for Vertebrate Genomics and the Howard Hughes Medical Institute.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteins Seek, Attack, Destroy Tumor Cells in Bloodstream
Using white blood cells to ferry potent cancer-killing proteins through the bloodstream virtually eliminates metastatic prostate cancer in mice, Cornell researchers have confirmed.
Friday, January 15, 2016
TB Bacteria's Trash-Eating Inspires Search for New Drugs
When hijacking a garbage truck, one might as well make use of the trash. That logic drives how tuberculosis-causing bacteria feed, say Cornell scientists.
Tuesday, June 11, 2013
Scientific News
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
A Metabolic Twist that Drives Cancer Survival
A novel metabolic pathway that helps cancer cells thrive in conditions that are lethal to normal cells has been identified.
Liver-On-Chip Tracks Dynamics of Cellular Function
Hebrew University’s liver-on-chip platform is uniquely able to monitor metabolic changes indicating mitochondrial damage occurring at drug concentrations previously regarded as safe.
Living Off the Fat of the Land
Do cancer cells synthesize the parts for new cells or scavenge them from the environment?
Liver Disease, Obesity Linked
Kanazawa University researchers find similarities in the impeded signalling between central insulin activity and glucose production in the liver for both obese mice and mice that have had the vagus nerve removed.
Decoding Ties Between Vascular Disease, Alzheimer’s
NIH consortium uses big data, team science to uncover complex interplay of factors.
Gene Identified that May Worsen Cancer Outcome
Some patients with breast cancer, lung cancer and leukaemia seem to fare poorly after treatment because of the effects of a particular gene, a new study finds.
‘Big Data’ Drills Down Into Metabolic Details
Rice University bioengineers introduce efficient way to analyze, compare tissue-specific pathways.
New Approach to Curbing Cancer Cell Growth
Using a new approach, scientists at The Scripps Research Institute (TSRI) and collaborating institutions have discovered a novel drug candidate that could be used to treat certain types of breast cancer, lung cancer and melanoma.
New Drug Delivery Method for Pancreatic Cancer
UCLA researchers use nanoparticles to send chemotherapy drug directly to the tumor site, reducing damage to healthy tissues.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!